X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fresenius Kabi Onco. with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs TEVA PHARMA (Israel) - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   TEVA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
TEVA PHARMA
Dec-13
FRESENIUS KABI ONCO./
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1763,026-   
Low Rs792,629-   
Sales per share (Unadj.) Rs37.71,736.8-  
Earnings per share (Unadj.) Rs5.1108.5-  
Cash flow per share (Unadj.) Rs6.7248.9-  
Dividends per share (Unadj.) Rs094.98-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs42.51,929.2-  
Shares outstanding (eoy) m158.23848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.6 207.4%   
Avg P/E ratio x25.026.1 95.9%  
P/CF ratio (eoy) x18.911.4 166.6%  
Price / Book Value ratio x3.01.5 204.1%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m20,1352,397,720 0.8%   
No. of employees `0001.244.9 2.6%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.232,768.2 15.8%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.62,047.0 34.2%   
INCOME DATA
Net Sales Rs m5,9631,472,765 0.4%  
Other income Rs m180-   
Total revenues Rs m5,9811,472,765 0.4%   
Gross profit Rs m1,430403,318 0.4%  
Depreciation Rs m258119,045 0.2%   
Interest Rs m-2628,928 -0.1%   
Profit before tax Rs m1,216255,345 0.5%   
Minority Interest Rs m01,160 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-167,620 0.0%   
Tax Rs m342-3,118 -11.0%   
Profit after tax Rs m80692,003 0.9%  
Gross profit margin %24.027.4 87.6%  
Effective tax rate %28.1-1.2 -2,304.6%   
Net profit margin %13.56.2 216.3%  
BALANCE SHEET DATA
Current assets Rs m5,102994,700 0.5%   
Current liabilities Rs m2,385867,463 0.3%   
Net working cap to sales %45.68.6 527.2%  
Current ratio x2.11.1 186.5%  
Inventory Days Days15091 165.2%  
Debtors Days Days11396 118.1%  
Net fixed assets Rs m5,148481,038 1.1%   
Share capital Rs m1583,625 4.4%   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,7321,635,963 0.4%   
Long term debt Rs m952753,058 0.1%   
Total assets Rs m10,3883,365,740 0.3%  
Interest coverage x-45.89.8 -465.8%   
Debt to equity ratio x0.10.5 30.7%  
Sales to assets ratio x0.60.4 131.2%   
Return on assets %7.53.6 209.0%  
Return on equity %12.05.6 212.9%  
Return on capital %14.64.9 296.1%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,274234,683 0.5%  
From Investments Rs m-1,204-83,158 1.4%  
From Financial Activity Rs m-196-281,518 0.1%  
Net Cashflow Rs m-126-129,993 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.5 Rs / USD

Compare FRESENIUS KABI ONCO. With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare FRESENIUS KABI ONCO. With: ELDER PHARMA  ALEMBIC PHARMA  UNICHEM LAB  CIPLA  SANOFI INDIA  



Today's Market

Sensex Opens Flat; Capital Goods & Banking Stocks Lag(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.5% while the Hang Seng is down 1.2%.

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

Laurus Labs Ltd (IPO)

Dec 6, 2016

Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - SUVEN LIFE COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS